dx.x.x deliverable name - i-hd d2... · salus-fp7-287800• d2.2.1 • version 1.0 • january...

SALUS “Scalable, Standard based Interoperability Framework for

Sustainable Proactive Post Market Safety Studies”

SPECIFIC TARGETED RESEARCH PROJECT

PRIORITY Objective ICT-2011.5.3b) Tools and environments enabling the re-use of

electronic health records

SALUS D2.2.1 Dissemination Plan

Due Date: January 31, 2013

Actual Submission Date: January 31, 2013

Project Dates: Project Start Date : February 01, 2012

Project End Date : January 31, 2015

Project Duration : 36 months

Deliverable Leader: The EuroRec Institute

Project co-funded by the European Commission within the Seventh Framework Programme (2007-2013)

Dissemination Level

PU Public X

PP Restricted to other programme participants (including the Commission Services)

RE Restricted to a group specified by the consortium (including the Commission Services)

CO Confidential, only for members of the consortium (including the Commission Services)

FP7-287800 SALUS

SALUS-FP7-287800• D2.2.1 • Version 1.0 • January 31st, 2013 of 41

Document History:

Version Date Changes From Review

V0.1 2012.09.12 Initial Document J. Devlies All

V0.2- 0.6 2013.01.25 Input from the consortia partners added;

editorial changes

J. Devlies,

L.Ciglenecki,

All

V1.0 2013.01.31 Final comments integrated Leo Ciglenecki,

Gokce Banu Leli

Contributors (Benef.) Jos Devlies (EuroRec), Leo Ciglenecki (EuroRec – Slovenia), Gunnar Declerck

(INSERM), Yves Parès (INSERM), Dirk Colaert (Agfa), Els Lion (Agfa), Gokce

Banu Laleci (SRDC), Mustafa Yuksel (SRDC), Ali Anil Sinaci (SRDC), Tomas

Bergvall (UMC), Bharat Thakrar (Roche), René Schippers (ERC), Andrea

Migliavacca (LISPA)

Responsible Author Jos Devlies Email [email protected]

Beneficiary EuroRec Phone +32-475-266148

FP7-287800 SALUS


SALUS Consortium Contacts:

Beneficiary Name Phone Fax E-Mail

SRDC Gokce Banu Laleci

Erturkmen

+90-312-2101763 +90(312)2101837 [email protected]

EUROREC Georges De Moor +32-9-2101161 +32-9-3313350 [email protected]

UMC Niklas Norén +4618656060 +46 18 65 60 80 [email protected]

OFFIS Wilfried Thoben

+49-441-9722131

+49-441-9722111

[email protected]

AGFA Dirk Colaert +32-3-4448408 +32 3 444 8401 [email protected]

ERS Gerard Freriks +31 620347088 +31 847371789 [email protected]

LISPA Alberto Daprà +390239331605 +39 02 39331207 [email protected]

INSERM Marie-Christine Jaulent +33142346983 +33153109201 marie-

[email protected]

TUD Peter Schwarz +49 351 458 2715 +49 351 458 7319 Peter.Schwarz@uniklinikum-

dresden.de

ROCHE Jamie Robinson +41-61-687 9433 +41 61 68 88412 [email protected]

FP7-287800 SALUS


EXECUTIVE SUMMARY

This deliverable reports on the dissemination activities by members of the SALUS consortium.

The first year of the project is mainly a year of user requirements definition, SALUS applications

design and the initial developments.

Dissemination is therefore mainly limited to awareness building and dissemination of SALUS initial

options and developments.

The consortium build its web site, defined how dissemination activities should be planned and

reported and realised yet several papers submitted and/or presented at conferences and/or workshops.

We also have an early journal article in IEEE TITB which is covered by SCI.

This deliverable is the first in a series of three deliverables addressing respectively year 1, year 2 and

year 3 of the project. This deliverable will each year be extended with new input and reports.

FP7-287800 SALUS


TABLE OF CONTENTS

Executive Summary ................................................................................................................................ 4 Table of contents ..................................................................................................................................... 5 Table of figures ....................................................................................................................................... 6 Overview of tables .................................................................................................................................. 6 1 Purpose ........................................................................................................................................... 7 2 Reference documents ..................................................................................................................... 7

2.1 Definitions and Acronyms ...................................................................................................... 7 2.2 Reference documents .............................................................................................................. 7

3 Task description ............................................................................................................................. 8 3.1 Task 2.2 Description in the DOW ........................................................................................... 8 3.2 Partners involved in WP2, Task 2.2 ........................................................................................ 9

4 Intellectual property ....................................................................................................................... 9 5 Communication and Dissemination plan ..................................................................................... 10

5.1 Purpose .................................................................................................................................. 10 5.2 Key Messages ....................................................................................................................... 10 5.3 Target Audiences .................................................................................................................. 10 5.4 Role of the Partners ............................................................................................................... 11 5.5 Salus Dissemination Report Form ........................................................................................ 11 5.6 Planned communication and dissemination activities ........................................................... 11 5.7 Publications ........................................................................................................................... 12 5.8 Internal Dissemination .......................................................................................................... 12 5.9 Metrics .................................................................................................................................. 12

6 Dissemination activities ............................................................................................................... 14 6.1 Logo and Salus Image ........................................................................................................... 14 6.2 Salus Web Site ...................................................................................................................... 15 6.3 Twitter Account .................................................................................................................... 16 6.4 Google+ Profile ..................................................................................................................... 16 6.5 Publications ........................................................................................................................... 18

6.5.1 International peer-reviewed .......................................................................................... 18 6.5.2 Other Publications, Articles, Newsletters, Press Releases ............................................ 18

6.6 Conferences ........................................................................................................................... 22 6.6.1 Papers, Posters and Presentations at Conferences ......................................................... 22 6.6.2 Attendance at Conferences ............................................................................................ 28

6.7 Presentations to authorities ................................................................................................... 28 6.8 Presentations to other projects and convergence activities ................................................... 28 6.9 Dissemination Material ......................................................................................................... 28 6.10 Metrics .................................................................................................................................. 29

ANNEX 1 Salus Fact Sheet ........................................................................................................... 31 ANNEX 2 Salus Poster .................................................................................................................. 33 ANNEX 3 Salus White Paper ........................................................................................................ 34 ANNEX 4 Dissemination report template ..................................................................................... 35 ANNEX 5 List of events-congresses ............................................................................................. 37

FP7-287800 SALUS


TABLE OF FIGURES

Figure 1: Salus Logo: extended ............................................................................................................ 14 Figure 2: Salus Logo: reduced .............................................................................................................. 14 Figure 3: Salus Web Site Home Page ................................................................................................... 15 Figure 4: Salus Twitter Account ........................................................................................................... 16 Figure 5: Salus Google+ page ............................................................................................................... 17 Figure 6: The SALUS project team in Istanbul – Photo published in the Uppsala Reports ................. 20 Figure 6a: Salus consortium meeting in Milano – Photo published in the Upsala Reports .................. 21 Figure 7: Dr. Gokce B. Laleci Erturkmen giving a presentation at MIE2012, Pisa.............................. 24 Figure 8: Web page statistics – by Audience ........................................................................................ 29 Figure 9: Web page statistics – by Location ......................................................................................... 30

OVERVIEW OF TABLES

Table 1 List of Abbreviations and Acronyms ......................................................................................... 7 Table 2 Project resources allocated to Task 2.2 ...................................................................................... 9 Table 3 Dissemination Metrics ............................................................................................................. 29

FP7-287800 SALUS


1 PURPOSE

The purpose of this Deliverable is to document the Salus Communication and Dissemination Strategy.

This Deliverable will also report on the Year 1 dissemination activities for the SALUS project.

Task 2.2 is part of Work Package 2 that intends to “identify the product(s) or product components that

can be derived from the project” and “to position them within the partner’s products offering” as well

as in the market.

Task 2.2 intends to define a dissemination plan and to coordinate dissemination activities in order to

optimize positioning of the project and the project results, considering the Exploitation Plan as

defined through Task 2.1.

2 REFERENCE DOCUMENTS

2.1 Definitions and Acronyms

Table 1 List of Abbreviations and Acronyms

Abbreviation/

Acronym DEFINITION

ADE Adverse Drug Event

CDISC Clinical Data Interchange Standards Consortium

CEN Committee Europeen de Normalisation

CRO Contract Research Organisation

DOW Description of Work

EC European Commission

EFPIA European Federation of Pharmaceutical Industries and Associations

EHR Electronic Health Record, Electronic Healthcare Record

EU European Union

HL7 Health Level Seven International

ICD-10 International Classification of Diseases

ICT Information Communication Technology

IP Intellectual Property

ISO International Standards Organisation

LOINC Logical Observation Identifiers Names and Codes

SALUS Scalable, Standard based Interoperability Framework for Sustainable Proactive Post

Market Safety Studies

SNOMED-CT Systematized NOMenclature of MEDicine

WHO World Health Organisation

2.2 Reference documents

The following documents were used or referenced in this document:

The Description of Work of the Salus project

Deliverable D1.1.1 of Salus project: “Salus Project Web Site”

Deliverable D2.1.1 of Salus project: “Exploitation Plan”

FP7-287800 SALUS


3 TASK DESCRIPTION

3.1 Task 2.2 Description in the DOW

The goal of Task 2.2 is to raise awareness about the approach and the results of the project; it will

prepare the ground for the exploitation of the SALUS results. It will seek synergies with other

initiatives and will establish cooperation links with them. Cooperation activities as such are addressed

in Task 2.4 and Deliverable D2.4.1.

The dissemination plan will define the consortium strategy and the list of actions for disseminating the

project results and will ensure wide dissemination of research and practical outcomes to related

standards bodies, research communities and the industry.

The dissemination activities can be listed as follows:

i. Organization of workshops and information days, which will usually coincide with related

bigger events such as conferences, to disseminate the progress achieved in the project and

collect feedback from external stakeholders,

ii. Publishing and presenting results within the scientific and industry community, including the

medical conferences and medical journals,

iii. Attendance to the main interchange of information forums, conferences, etc,

iv. Representation of the European Commission at the international events when requested by the

EC,

v. Conducting successful pilots with players of the Clinical Research Industry,

vi. Presentation to local and state authorities,

vii. Participation in concertation activities with other ICT funded projects related to the area of

the project and organised by the European Commission. Dissemination and travel resources

allocated to the SALUS consortium ensure participation to these activities.

viii. Supporting interested developers by publicising the availability of open source tools and

documentation,

ix. Disseminating project information in the European research community through research

clusters,

x. Support of international standards development in support of results, specifically in the areas

of healthcare terminologies, regulated clinical research studies and EHR/PHR exchange

standards and profiles,

xi. Support for European interest and recognition of European standards,

xii. Active participation in the closely related committees and meetings specifically CEN TC251

WGs, ISO TC215 WGs, HL7, IHE, CEN 13606, openEHR, CDISC, SNOMED-CT, ICD-10,

LOINC for sharing the experience and results achieved during the project with these bodies, xiii. Press releases at project start and at major milestones;

xiv. The project website will be kept updated with news, public deliverables, articles and material

from participation at events (e.g., slides of presentations, keynote speeches, articles in

journals and conference proceedings).

In addition to these, a SALUS White Paper will be developed describing the vision and the strategy of

the project in early phases of the project for wide distribution of project vision and results to the

stakeholders. The White Paper is periodically revised according to the progress made by the project.

As a roadmap to Green Field Member states, we will prepare a guidance note presenting the SALUS

standard based interoperability profiles for conducting post market safety studies, the common core

data set that will enable sharing clinical care data available in EHR systems for post market safety

studies, and the open source toolsets provided by SALUS project. These interoperability profiles

together with the common core data set will serve as a roadmap for “green field” member states: the

FP7-287800 SALUS


systems that will be built from scratch can be developed in accordance to these interoperability

interfaces by making use of the open source toolsets provided.

The “Dissemination Plan” will be first issued after the first year; revisions will be submitted to the

Project Management Board yearly.

Finally in accordance with Article II.30 - All SALUS dissemination activities will be reported in the

plan for the use and dissemination of foreground, including sufficient details/references to enable the

Commission to trace the activity. With regard to scientific publications relating to foreground

published before or after the final report, such details/references and an abstract of the publication will

be provided to the Commission at the latest two months following publication.

Furthermore, an electronic copy of the published version or the final manuscript accepted for

publication will also be provided to the Commission at the same time for the purpose set out in Article

II.12.2 if this does not infringe any rights of third parties.

3.2 Partners involved in WP2, Task 2.2

Table 2 Project resources allocated to Task 2.2

SD

RC

EU

RO

RE

C

UM

C

OF

FIS

AG

FA

ER

S

LIS

PA

INS

ER

M

TU

D

RO

CH

E

TO

TA

L P

M

T2.4 1 7 2 1 1 1 2 2 1 1 19.0

4 INTELLECTUAL PROPERTY

This document is public and can be reused by whoever interested to do so.

Though the project is committed to offer as much as possible open source free available products and

services, some products or services reported / described in this deliverable may be IP protected based

on the consortium agreement. A specific “Intellectual Property Rights Agreement” is provided and

available on the Salus web site as deliverable D2.3.1.

FP7-287800 SALUS


5 COMMUNICATION AND DISSEMINATION PLAN

This communication and dissemination plan is based on the definition of key messages to be

addressed at defined target audiences

5.1 Purpose

This communication and dissemination plan intends to set a number of guidelines for the consortium

partners and to suggest a number of tools to raise awareness about the project, the options taken by the

consortium and the products as well as the services resulting from the project.

5.2 Key Messages

Communication and Dissemination requires concise and clear key messages addressed at appropriate

target audiences.

The content evolves and becomes more and more concrete and “interesting” over time, considering

the progressive completion of the project.

Create awareness about the project as such and the expected results of the project will therefore be the

initial message, surely in the first year of the project. It will promote and deepen the understanding of

the project.

More domain oriented messages are at the start of the project consist of more objectives, expected

conclusions of the project rather than realisations.

The consortium identified a preliminary list of key messages, key expectations, to be proved during

the lifetime of the project.

On-site drug monitoring can improve patient safety, based on known and well documented

risks for Adverse Events.

The use of high quality standards based EHR data improves efficiency of ADE monitoring.

EHR data can be used for detection and early warning of unknown risks for patient safety,

provided.

Salus will provide tools enabling to increase efficiency of ADE reporting by integrating EHR

data into that process.

This list will evolve during the lifetime of the project.

5.3 Target Audiences

The consortium identified a number of directly targeted audiences:

National and International Drug Agencies, Pharmacovigilance Institutes or Organisations and

by extension other Public Health Agencies;

Clinical Research Organisations;

Pharmaceutical Industry;

EHR system providers;

Healthcare Professionals, users of the EHR applications.

FP7-287800 SALUS


The patients and the Health Authorities are interested and involved parties, mainly as beneficiaries of

any improved drug related patient safety.

5.4 Role of the Partners

All project partners should contribute to the communication and dissemination activities. It is a

common challenge. This contribution can be done in different ways:

providing on regular basis information on the progress of their work, their involvement in

the project,

contributing to the production of the promotional material,

suggesting conferences and meeting where Salus may be presented or organise a

workshop,

providing source material for press conferences and/or the web site,

preparing publications.

EuroRec is leading this task in close partnership with the coordinator.

Partners are free to suggest dissemination activities and to attend them, on their own budget. They

should nevertheless report on these activities (see 5.5). They should also contact the project

coordinator and/or the dissemination task responsible in order to optimise awareness for the project.

5.5 Salus Dissemination Report Form

A form to report dissemination activities has been developed.

The form is attached as Annex 3.

5.6 Planned communication and dissemination activities

The selected and planned dissemination activities are standard. They are and will be focused on the

target audiences and on favouring cooperation with other projects in the ‘cluster’ for secondary use of

EHR data and on Pharmacovigilance.

The DOW listed under the task description Task 2.2 a number of actions and activities as examples of

efficient communication and dissemination. See chapter 3.1.

The following activities, yet in use, reported in the next chapter, were listed:

Logo and Templates to increase image of the project,

Web site,

Use of other social media such as Twitter,

Dissemination material: flyer, white paper, Salus Fact Sheet,

Presenting the project at Conferences as poster or as papers,

Publishing Journal articles in Journals having a high impact factor

Direct contact with National and International Drug Agencies.

An initial list of possibly interesting “meetings” or events was published on the Salus web site, for

internal use. That list will be updated regularly.

The most recent version of the list is attached as Annex 4, as per January 2013.

FP7-287800 SALUS


5.7 Publications

The consortium will favour and expect to realise some international peer-reviewed publications

during the lifetime of the project. These publications might be on the project as such or regarding any

related topic, mentioning the project as a reference.

All publications about Salus or referring to activities within the Salus project or mentioning results of

the Salus project should be submitted to the project consortium prior to their publication. The Project

Management Board will have the final word in case of non-agreement between the coordinator and a

candidate publisher.

All partners are encouraged to submit such publications. They should nevertheless include all

partners, individuals involved in task they are reporting about.

All publications should mention “The Salus Project is research project partially funded by the

European Commission, contract FP7-ICT-2011-7-287800”.

5.8 Internal Dissemination

Some of the project partners have strong relations with either national authorities or international

pharmacovigilance centres of expertise. They should provide a particular effort in creating awareness

about the Salus project.

UMC will create awareness of the SALUS project with the national authorities through the

newsletter called Uppsala Reports and the annual pharmacovigilance course hosted by UMC

in Uppsala.-

EuroRec should create awareness within its network of National ProRec centres.

Lombardia Informatica SpA (from the Lombardia Region) and INSERM (Public French

Institute) are expected to promote Salus concepts and options to their regional and/or national

authorities.

Roche on the other hand, being involved in several project addressing the issue of pharmacovigilance

and being a directly interested party to profit from the Salus project, is to create awareness within the

EFPIA organisation of pharmaceutical industries.

5.9 Metrics

A set of data will be defined and collected to evaluate and improve progressively the effectiveness of

the communication and dissemination activities.

The following data are listed as potential indicators of appropriateness of communication and

dissemination activities:

Number of Web Site visitors

Average number of pages opened by the web site visitors

Number of requests for information

Number of downloads

Number of peer-reviewed publications

FP7-287800 SALUS


Number of other publications

Number of presentations at Salus Workshops or at Conferences

Number of attendees at Salus Workshops or at Conferences

Number of Conferences with a Salus delegation

Number of Salus collaborators present at Conferences

Number of meetings / contacts1 with National and/or International Drug Agencies

Number of meetings / contacts with Public Health Agencies

Number of meetings / contacts with Pharmacovigilance Institutes

Number of meetings / contacts with CROs

Number of meetings / contacts with Pharmaceutical Industry

Number of meetings / contacts with EHR system providers

Contacts with Healthcare Professionals

A number of these indicators might be into one or two indicators, e.g. public authorities and private

parties.

A final selection will be made after the first year of the project.

1 A contact can be a meeting or even a request for information regarding the project or regarding a specific

domain related aspect.

FP7-287800 SALUS


6 DISSEMINATION ACTIVITIES

We report in this section the dissemination activities of Year 1 of the project.

The first step, even before the start of the project, was to create a mark, a visual identity, developing a

logo and document style.

6.1 Logo and Salus Image

Creating and using consistently a Salus Style is a first step toward improving awareness through

enhancing recognisability of the project.

The following identity material was created and made available from the start of the project:

- Logo

- Presentation template (potx file)

- Deliverable template (dotx file)

Two logos have been designed for SALUS Project.

One with the Project full name, another a more compact one including only the Logo image.

The standard colour used in the Logo and the text is:

Figure 1: Salus Logo: extended

Figure 2: Salus Logo: reduced

The Salus standard colour is:

RGB: 4, 160, 185

HTML: #04A0B9

FP7-287800 SALUS


6.2 Salus Web Site

The Project Web Site was on line at the very early stage of the project, as documented in Deliverable

D1.1.1. (Month 2)

Figure 3: Salus Web Site Home Page

SALUS Web Site is composed of two parts: the public SALUS Web site and the restricted Document

Management site. The public Web site aims to give an overview of SALUS project presenting its

objectives, work packages, partners, and to present latest achievements through the respective public

FP7-287800 SALUS


SALUS deliverables, publications and dissemination material. SALUS events will also be announced

through SALUS Web site. It will also provide references to open source SALUS components and

prototype demonstrations. SALUS Web site also hosts a restricted Document Management site, to be

used by SALUS partners as a virtual file manager to collaboratively work on SALUS documents and

share information. It will be the living document archive of SALUS project.

Partners are requested to promote awareness of the project and public exposure of the web site by

providing a link to the SALUS web site on their own web site.

6.3 Twitter Account

The Consortium started a twitter account as a complementary way to improve communication. The

account is: https://twitter.com/SALUSProject_EU.

The number of followers is expected to increase and to give an indication on the communication and

dissemination activities of the consortium.

Figure 4: Salus Twitter Account

6.4 Google+ Profile

The consortium has a Google+ profile: https://plus.google.com/u/0/115735001413164059789/

https://twitter.com/SALUSProject_EU

https://plus.google.com/u/0/115735001413164059789/

FP7-287800 SALUS


Figure 5: Salus Google+ page

FP7-287800 SALUS


6.5 Publications

6.5.1 International peer-reviewed

6.5.1.1 Publication in the Journal "IEEE Transactions on Information Technology in

Biomedicine"

Title of the paper: “Providing Semantic Interoperability between Clinical Care and Clinical

Research Domains”.

Authors: Gokce B. Laleci Erturkmen, Asuman Dogac, Mustafa Yuksel (SRDC)

Note: Paper has been accepted for the publication in the "IEE Transactions on Information

Technology in Biomedicine" Journal.

The full version of the paper is available at the Salus web site:

http://srdc.com.tr/publications/2012/SALUSSemanticInteroperability.pdf

Abstract: The efficiency with which clinical research studies are conducted affects faster

medication innovation and decreases time to market for new drugs. To increase this

efficiency, the parties involved in a regulated clinical research study, namely, the

sponsor, the clinical investigator and the regulatory body, each with their own

software applications, need to exchange data seamlessly. However, currently, the

clinical research and the clinical care domains are quite disconnected because each

use different standards and terminology systems.

In this article, we describe an initial implementation of the Semantic Framework

developed within the scope of SALUS project to achieve interoperability between

the clinical research and the clinical care domains. In our Semantic Framework, the

core ontology developed for semantic mediation is based on the shared conceptual

model of both of these domains provided by the BRIDG initiative. The core

ontology is then aligned with the extracted semantic models of the existing clinical

care and research standards as well as with the ontological representations of the

terminology systems to create a “model of meaning” for enabling semantic

mediation. Although SALUS is a research and development effort rather than a

product, the current SALUS knowledge base contains around 4.7 million triples

representing BRIDG DAM, HL7 CDA model, CDISC standards and several

terminology ontologies. In order to keep the reasoning process within acceptable

limits without sacrificing the quality of mediation, we took an engineering approach

by developing a number of heuristic mechanisms. The results indicate that it is

possible to build a robust and scalable semantic framework with a solid theoretical

foundation for achieving interoperability between the clinical research and clinical

care domains.

6.5.2 Other Publications, Articles, Newsletters, Press Releases

6.5.2.1 Communication published in the Uppsala Reports (1)

Title of the communication: “SALUS lift off in Istanbul”.

FP7-287800 SALUS


Authors: Tomas Bergvall (UMC) on behalf of the SALUS Consortium

Note: This short communication was published in the Uppsala Reports, Sweden, which is

a newsletter reaching about 3.000 subscribers.

Content: It is generally agreed that pre-approval clinical trials cannot guarantee that drugs

will not have serious side effects after they are marketed. Although post-approval

drug safety data studies aim to address this problem their effectiveness is being

examined closely following recent examples of drug withdrawals. This is mainly

because current post market safety studies largely depend on submission of

spontaneous case reports, where under-reporting is a major problem. A more

proactive approach is needed, where safety data from multiple sources are actively

monitored, linked and analyzed. Effective integration and utilization of electronic

health records (EHR) can help to improve post-market safety activities.

A new project, SALUS (after the Roman goddess of health and Latin for salvation)

aims to automatically detect adverse drug events (or reactions) in EHR, highlighting

the detected events to the treating physician and creating procedures for sending the

reports to regulatory authorities. Another main objective is the development of

methods to enable exploratory signal detection in EHR data. The focus will be on

exploratory analysis in EHR data based on signals found in VigiBase data to

enhance the signal detection procedure with the data available in different EHR

sources.

The project partners are Software Research and Development and Consultancy Ltd

(SRDC, Turkey), The European Institute for Health Records (EuroRec, France), the

UMC (Sweden), the Oldenburg Research and Development Institute for Information

Technology Tools and Systems (OFFIS, Germany), Agfa (Belgium), the Electronic

Record Services (Netherlands), Lombardia Informatica (LISPA, Italy), Institut

National de la Santé et de la Recherche Médicale (INSERM, France), the Dresden

Institute of Technology (Germany), and F. Hoffmann – La Roche (Switzerland).

The outcome of the project will be an open source software tool which it will be

possible to implement on top of any EHR system with web services that

communicate between the different parts of the system.

For more information regarding the project please visit http://www.salusproject.eu

The kickoff meeting organized by SRDC, the project coordinators in Istanbul, had a

bit of a rocky start, with all the meeting delegates being delayed 12 hours due to

heavy snow in Istanbul. The project finally got off the ground anyway and was

topped off by a visit to the Nar Lokanta restaurant (www.narlokantasi.com) for a

great dinner and a showcase of old Turkish art.

https://mail.who-umc.org/owa/redir.aspx?C=252327841b1f4b0d8eb1bc4e735b0523&URL=http%3a%2f%2fwww.salusproject.eu

https://mail.who-umc.org/owa/redir.aspx?C=252327841b1f4b0d8eb1bc4e735b0523&URL=http%3a%2f%2fwww.narlokantasi.com

FP7-287800 SALUS


Figure 6: The SALUS project team in Istanbul – Photo published in the Uppsala Reports

6.5.2.2 Communication published in the Uppsala Reports (2)

Title of the communication: “Providing Semantic Interoperability between Clinical Care and

Clinical Research Domains”.

Authors: Tomas Bergvall (UMC) on behalf of the SALUS Consortium

Note: This short communication was published in the Uppsala Reports, Sweden, which is

a newsletter reaching about 3.000 subscribers.

Content:

The SALUS Interoperability Approach

Pre-approval clinical trials cannot guarantee that drugs will not have serious side

effects after they are marketed. Post-approval drug safety data studies aim to address

this problem, however, their effectiveness is questioned especially after recent

examples of drug withdrawals. A contributing reason is that current post market

safety studies largely depend on the submission of spontaneous case reports where

underreporting is a major problem. The need for a more proactive approach is

apparent, where safety data from multiple sources are actively monitored, linked and

analyzed. Effective integration and utilization of electronic health records (EHR)

can help to improve post-market safety activities on a proactive basis. SALUS aims

to facilitate this through providing functional interoperability profiles and

supporting open source toolsets enabling EHR systems and clinical research systems

to communicate and exchange EHR data.

FP7-287800 SALUS


The SALUS Consortium believes that an effective integration and utilization of

electronic health record (EHR) data can help to improve post-market safety

activities and will result in:

Strengthening the spontaneous reporting process by automated ADE detection

Enabling ADE reporting by extracting the available information from EHRs

into the individual case safety reports to avoid double data entry.

Strengthening the current signal detection processes by enabling case reports

to be traced to their corresponding patient records.

Enabling real time screening of multiple, distributed, heterogeneous EHRs for

early detection of ADE signals.

Enabling sustainable and scalable EHR data re-use facilitating wide scale

outcome and health effectiveness research.

SALUS Project (http://www.salusproject.eu), an R&D project co-financed by the

European Commission's 7th Framework Programme (FP7), aims to create the

necessary semantic and functional interoperability infrastructure to enable secondary

use of EHR data in an efficient and effective way for reinforcing the post market

safety studies.

For more information please read the whitepaper presented at the project website

(http://www.salusproject.eu/docs/SALUSwhite_paper-Final.pdf), join us on twitter

(SALUSProject_EU) or Google+ (Salus Project).

Figure 7a: Salus consortium meeting in Milano – Photo published in the Upsala Reports

http://www.salusproject.eu/

http://www.salusproject.eu/

FP7-287800 SALUS


6.6 Conferences

Stimulated by the list of potential events published on the Salus web site (see Annex 4), and upon the

initiatives of the individual partners in the consortium, the project has yet been presented at several

events.

The hereby listed items comprise presenting/giving papers, posters and presentations at the

conferences, as well as active attendance at the conferences or workshops on medical informatics

and/or pharmacovigilance.

We are not listing in this deliverable the presentations and/or interventions done at collaborating

project meetings, as e.g. EHR4CR meetings.

6.6.1 Papers, Posters and Presentations at Conferences

6.6.1.1 SIMI 2012 Paper – Crete, Greece, May 2012

Title of the paper: Building the Semantic Interoperability Architecture Enabling Sustainable

Proactive Post Market Safety Studies

Authors: Gokce B. Laleci Erturkmen, Asuman Dogac, Mustafa Yuksel, Sajjad Hussain,

Gunnar Declerck, Christel Daniel, Hong Sun, Kristof Depraetere, Dirk Colaert, Jos

Devlies, Tobias Krahn, Bharat Thakrar, Gerard Freriks, Tomas Bergvall, Ali Anil

Sinaci

Note: The paper was submitted and accepted as a short presentation to the “Extended

Semantic Web Conference 2012” in Crete, Greece, May 27-31, 2012.

The full text of the paper is available on the website of SRDC

http://www.srdc.com.tr/projects/salus/docs/SALUSSIMIPaperFinal.pdf and on the

Salus Website \Documentation Materials\Publications.

Abstract: Pre-approval clinical trials cannot guarantee that drugs will not have serious side

effects after they are marketed. Post-approval drug safety data stud-ies aim to

address this problem, however, their effectiveness is started to be dis-cussed

especially after recent examples of drug withdrawals. This is due to the fact that,

current post market safety studies largely depend on the submission of spontaneous

case reports where underreporting is a major problem. The need for a more

proactive approach is apparent, where safety data from multiple sources are actively

monitored, linked and analyzed. Effective integration and utilization of electronic

health records (EHR) can help to improve post-market safety activities on a

proactive basis. SALUS aims to facilitate this through providing functional

interoperability profiles and supporting open source tool-sets enabling EHR systems

and clinical research systems to communicate and exchange EHR data;

implementing semantic interoperability solutions enabling meaningful interpretation

of the exchanged EHR data; implementing security and privacy mechanisms and

open source toolsets ensuring that clinical information is shared in an ethical and

safe way and providing a novel exploratory analysis framework for open-ended

temporal pattern discovery for safety studies on top of disparate, distributed,

heterogeneous EHR Systems.

http://www.srdc.com.tr/projects/salus/docs/SALUSSIMIPaperFinal.pdf

FP7-287800 SALUS


6.6.1.2 SIMI 2012 Poster - Crete, Greece, May 2012

SALUS was also represented by a poster in the poster session. The poster is added in Annex 2

and available on the web site of SRDC as well as on the Salus web site \Documentation

Materials\Publications.

http://www.srdc.com.tr/projects/salus/docs/poster_SALUS_SIMI2012.pdf

6.6.1.3 MIE 2012 Conference Paper – Pisa, Italy, August 2012

Title of Paper / Publication: SALUS: Scalable, Standard based Interoperability Framework for

Sustainable Proactive Post Market Safety Studies

Authors: Gokce B. Laleci Erturkmen, Asuman Dogac, Mustafa Yuksel

Note: A presentation was given on August 29, 2012 by Dr. Gokce B. Laleci Erturkmen with as

title “SALUS: Scalable, Standard based Interoperability Framework for Sustainable Proactive

Post Market Safety Studies” in the Track 04.03 “Enhancing Research and Trials”.

Abstract: SALUS aims to facilitate resuse of EHRs for enabling pro-active post market safety

studies through providing functional and semantic interoperability profiles and

supporting open source toolsets enabling EHR systems and clinical research systems

to communicate and exchange EHR data and meaningful interpretation of the

exchanged EHR data. Implementing security and privacy mechanisms and open

source toolsets are also essential ensuring that clinical information is shared in an

ethical and safe way. Finally SALUS aims to provide a novel exploratory analysis

framework for open-ended temporal pattern discovery for safety studies on top of

disparate, distributed, heterogeneous EHR Systems.

The full text as well as the slides are available on the Salus Web Site \Documentation

Materials\Publications.

Information about the MIE2012 is available on www.mie2012.it

http://www.srdc.com.tr/projects/salus/docs/poster_SALUS_SIMI2012.pdf

http://www.mie2012.it/

FP7-287800 SALUS


Figure 8: Dr. Gokce B. Laleci Erturkmen giving a presentation at MIE2012, Pisa

6.6.1.4 A Tutorial at International Conference on Very Large Databases (VLDB) - Istanbul, Turkey, November 2012

Title of the presentation: Interoperability in eHealth Systems (Tutorial)

Author: Prof. Dr. Asuman Dogac (SRDC)

Note: Prof. Dr. Asuman Dogac has given a tutorial on “Interoperability Issues in eHealth

Domain”. Interoperability challenge between clinical care and research domain was

one of the main topics addressed. SALUS technical and semantic interoperability

solutions have been presented to the audience.

Around 50 people attended the Tutorial. (More on the conference and tutorial: http://www.vldb2012.org/)

6.6.1.5 A Presentation at ApacheCon EU - Sinsheim, Germany; November 2012

Title of the presentation: Jena based Implementation of a ISO 11179 Meta-data Registry

Author: A. Anil Sinaci, M.Sc. (SRDC)

Note: Author presented the design and initial implementation of CDE Repository at the

Linked Data Track of the ApacheCon EU conference in Germany

http://www.apachecon.eu/

Description and Abstract of the presentation:

http://www.apachecon.eu/schedule/presentation/66/ The presentation: http://www.slideshare.net/sinaci/jena-based-implementation-

of-a-iso-11179-meta-data-registry-15066461

http://www.vldb2012.org/

http://www.apachecon.eu/

http://www.apachecon.eu/schedule/presentation/66/

http://www.slideshare.net/sinaci/jena-based-implementation-of-a-iso-11179-meta-data-registry-15066461

http://www.slideshare.net/sinaci/jena-based-implementation-of-a-iso-11179-meta-data-registry-15066461

FP7-287800 SALUS


Abstract: ISO 11179 defines a meta-data registry (MDR); describes how to describe data,

store data, classify data and manage data. The standard follows a bottom-up

strategy; registers common data elements to the registry, then builds the larger

elements by aggregation and association of these elements. It can be seen as an early

implementation of the semantic requirements for the data interoperability of

different applications, hence enterprises. The standard exhibits a relational data

model which describes the MDR through entity-relationship diagrams. However,

current experience states that data is becoming very big with several inter-links, and

data management paradigms change in order to be able to process such linked data.

On the other hand, semantic technologies based on RDF processing and ontology

reasoning exhibits more advanced semantic processing options for the sake of

interoperability.

This talk introduces a Jena based implementation of a standard meta-data

registry/repository which brings semantic processing capabilities on top of the

Common Data Elements. Processing linked data through a common data element

repository which is backed by Jena TDB, not only preserves the relational nature of

the standard MDR model, but also exposes the non-relational features of the linked

data. Hence, reasoning and other semantic functionalities are provided at the back-

end implementation while hiding the triple-store related details from the API

consumer.

6.6.1.6 A Position paper at SWAT4LS Workshop - Paris, France; November 2012

Title of the paper: Semantic-sensitive extraction of EHR data to support adverse drug event

reporting

Authors: Gunnar Declerck, Sajjad Hussain, Yves Parès, Christel Daniel, Mustafa Yuksel, Ali

Anil Sinaci, Gokce Banu Laleci Erturkmen, Marie-Christine Jaulent (all INSERM

UMRS and SRDC)

Note: The authors submitted a position paper describing ICSR reporting tool to the

SWAT4LS Workshop, held in Paris on November 30th, 2012

(http://www.swat4ls.org/workshops/paris2012/)

The full version of the paper is available at the Salus web site:

http://www.srdc.com.tr/projects/salus/docs/ICSR_Reporting_Tool_SWAT4LS_V2.

Abstract: The reasons behind adverse drug events (ADE) getting underreported by medical

professionals are overlooking complex drug reactions and dealing with cumbersome

manual process of reporting ADE based on patient profiles. We present an initial

design of SALUS ICSR reporting tool that supports the reporting of ADE to

regulatory authorities with services (i) enabling automatic prepopulation of

reporting forms by extracting patient data from EHR and (ii) presenting pre-filled

reporting forms to medical professionals for further completion and validation. The

main objective of this tool is to ease the process of filling ADE reporting forms and

increase the quality of reported data. To enable the compatibility of our reporting

tool with heterogeneous EHR data models, SALUS interoperability platform

supports the patient data extraction process and ensures the reporting of ADE in a

standardized format expected by regulatory authorities.

http://www.swat4ls.org/workshops/paris2012/

FP7-287800 SALUS


6.6.1.7 AMIA 2013 Clinical Research Informatics Summit Panel – San Francisco, USA,

March 2013

Title of the paper: Standard-based integration profiles for clinical research and patient safety

Authors: Christel Daniel, MD, PhD, Gokce Banu Laleci Erturkmen, PhD , Ali Anil Sinaci,

MSc , Brendan C Delaney, BM, BCh, MD, Vasa Curcin, PhD, Landen Bain

Note: Together with EHR4CR and TRANSFoRm projects, we have prepared a panel

discussion proposal on "Standard-based integration profiles for clinical research and

patient safety" for 2013 AMIA Clinical Research Informatics Summit, to be held on

March 20-22 in Boston, USA. This panel proposal has been accepted.

Abstract: EHRs can now be adapted to integrate seamlessly with existing research platforms.

However, key challenges need to be overcome in order to provide a platform that

functions across many EHR systems.

The IHE Quality, Research and Public Health (QRPH) domain addresses the

information exchange standards necessary to share information relevant to quality

improvement in patient care and clinical research. In collaboration with CDISC’s

Healthcare Link initiative, IHE QRPH has developed a set of integration profiles

that specifically address EHR-enabled research.

The panel participants from three European projects will present how subsets of

existing IHE QRPH profiles can be pulled together (and extended when necessary)

to form a super profile which will standardize and automate the clinical trial process

flow.

The EHR4CR project is providing adaptable, reusable and scalable tools and

services for reusing data from hospital EHRs for Clinical Research. TRANSFoRm

is developing an informatics infrastructure to support the learning healthcare system

in European Primary Care. SALUS project is providing scalable, standard based

interoperability framework for sustainable proactive post market safety studies.

Overall, the panel will discuss the key steps towards realizing a joint

EHR4CR/TRANSFoRm/SALUS European projectathon demonstrating EHR-

enabled clinical research across Europe using standard-based integration and content

profiles.

6.6.1.8 MedeTel 2013 Conference paper - Luxemburg, April 2013

Title of the paper: Security and Privacy Issues for enabling the Secondary use of EHRs in

Clinical Research

Authors: Elif Eryilmaz, Gokce B. Laleci Erturkmen (SRDC)

Note: The authors submitted an abstract to MedeTel 2013 conference about SALUS

Security/Privacy architecture, which has been accepted for presentation.

The full version of the paper will be available at the SALUS web site after the

conference.

Abstract: Re-using Electronic Healthcare Records (EHR) for facilitating clinical research

studies has a great potential. Besides interoperability, safeguarding the security and

privacy of the medical data in the context of secondary use for clinical research is

one of the most important challenges in this respect. In this presentation we will

introduce the SALUS security architecture, including de-identification and

pseudonymization mechanisms applied to the queried clinical instances as well as

additional security services compatible with IHE ATNA Profile that guarantees the

safe use of EHRs for the clinical research studies.

FP7-287800 SALUS


6.6.1.9 MedInfo 2013 Conference paper - Copenhagen, Denmark; August 2013

Title of the paper: Building a time-saving and adaptable tool to report adverse drug events

Authors: Yves Parès, Gunnar Declerck, Sajjad Hussain, Romain Ng, Marie-Christine Jaulent

(INSERM)

Note: Authors submitted a paper for MedInfo 2013 conference, Copenhangen, August

2013, describing the design, state of realization and plans for the ICSR reporting

tool. It extends previous paper for the SWAT4LS workshop.

The full version of the paper will be available at the Salus web site after the

conference.

Abstract: The difficult task of detecting adverse drug events (ADEs) and the tedious process

of building manual reports of ADE occurrences out of patient profiles results in a

majority of adverse reactions not being reported to health regulatory authorities. The

SALUS individual case safety report (ICSR) reporting tool, a component currently

developed within the SALUS project, aims at supporting semi-automatic reporting

of ADEs to regulatory authorities. We present its initial design and current state of

realization. The features it brings are (i) automatic pre-population of reporting forms

through extraction of the patient data contained in an Electronic Health Record

(EHR), (ii) generation and electronic submission of the completed ICSRs by the

physician to regulatory authorities and (iii) integration of the reporting process into

the physician's work-flow to limit the disturbance. The objective is to increase the

rates of ADE reporting and the quality of the reported data. The SALUS

interoperability platform supports patient data extraction independently of the EHR

data model in use and allows generation of reports using the format expected by

regulatory authorities.

6.6.1.10 MedInfo 2013 Conference paper - Copenhagen, Denmark; August 2013

Title of the paper: An Extensible Security Infrastructure for the Secondary Use of EHRs

represented in HL7 Clinical Document Architecture for Clinical Research

Authors: Elif Eryilmaz, Gokce B. Laleci Erturkmen (SRDC)

Note: The authors submitted a paper to MedInfo 2013 conference about SALUS

Security/Privacy architecture.

The full version of the paper will be available at the Salus web site after the

conference.

Abstract: Re-using Electronic Healthcare Records (EHR) for facilitating clinical research

studies has a great potential. Besides interoperability, safeguarding the security and

privacy of the medical data in the context of secondary use for clinical research is

one of the most important challenges in this respect. In order to ensure that the

clinical information is shared among EHR systems and clinical research systems in

an ethical and safe way, there needs to be standards-based and adaptable security

FP7-287800 SALUS


and privacy mechanisms that can be used by both clinical care and clinical research

parties in an interoperable manner. In this respect, we aim to develop an extensible

security infrastructure that supports re-use of the EHRs represented in t HL7

Clinical Document Architecture (CDA) format for strengthening the post-approval

drug safety studies in the area of clinical research. Our work involves

implementation of the security architecture, including novel data protection

mechanisms applied to the queried clinical instances represented in CDA as well as

additional security services compatible with standard profiles that guarantees the

safe use of EHRs for the clinical research studies.

6.6.2 Attendance at Conferences

We will report in this section all attendance to international conferences and/or workshops on

medical informatics and/or pharmacovigilance.

Partner Date

(yyyy/mm) Name of the Conference / Workshop - Title Location Country

Number

attending

SDRC 2012/05 Extended Semantic Web Conference 2012 Crete, Greece 1

SDRC 2012/08 MIE2012 Pisa, Italy 1

ERS 2012/08 MIE 2012 Pisa, Italy 2

SRDC 2012/11 ApacheCon EU Sinsheim,

Germany 1

ROCHE 2012/08

28th International Conference on

Pharmacoepidemiology & Therapeutic Risk

Management in Barcelona,

Barcelona, Spain 2

INSERM 2012/11 SWAT4LS Workshop Paris, France 2

6.7 Presentations to authorities

LISPA in function of statutory relationship with Lombardy Region presented the project Salus to

Regional Government Health Ministry. LISPA met in May 31st 2012 Dr. Luca Merlino, Health

Ministry vice director, Dr. Alma Lisa Rivolta Regional Pharmacovigilance Office Director. Dr.

Merlino asked to the Regional Pharmacovigilance Office to cooperate and support Lispa in the

project.

On December 18th 2012 an informal meeting took place with Dr. Fernanda Ferrazin Post Marketing

Surveillance Department Coordinator, Head of Pharmacovigilance Office (AIFA). During the meeting

Dr. Ferrazin proposed to organize a work shop with AIFA in second semester 2013.

6.8 Presentations to other projects and convergence activities

These activities are reported in Deliverable D2.4.1 on Cooperation and Collaboration.

6.9 Dissemination Material

The dissemination material is made available to the partners and to the public on the Salus web site.

The actual dissemination material consists of

Salus ID Card (Salus Fact Sheet), available on the web. See also Annex 1.

FP7-287800 SALUS


Salus White Paper, available on the web site. See also Annex 3.

Flyers

Brochures

6.10 Metrics

The consortium expects to measure its communication and dissemination activities twice a year, from

the end of Year 1 on.

The final selection of the metrics data will be made after the first year of the project.

For the Year 1, the following metrics have been recorded and listed in the following table:

Observed period

Visits on the web site

Sep-Dec 829

Publications

2012 3

Papers, posters, presentations at

conferences

2012 6 in 2012 (an additional 2 (1

presentation, 1 Panel)

submitted and accepted for

2013 and 2 conference

presentations submitted for

2013 awaiting decision)

Table 3 Dissemination Metrics

In addition, a more detailed web page statistics have been produced for Q4 2012. They present data on

visits to the project's web page, analysed by types of audience and location of the visitors.

Figure 9: Web page statistics – by Audience

FP7-287800 SALUS


Figure 10: Web page statistics – by Location

FP7-287800 SALUS


ANNEX 1 SALUS FACT SHEET

FP7-287800 SALUS


FP7-287800 SALUS


ANNEX 2 SALUS POSTER

FP7-287800 SALUS


ANNEX 3 SALUS WHITE PAPER

Salus White Paper (pages 1-2 and 11-12)

FP7-287800 SALUS


ANNEX 4 DISSEMINATION REPORT TEMPLATE

Dissemination Report / Suggestion2

Purpose of the form

The form should be used to report/document as well as to suggest dissemination activities linked to the Salus project.

The form should be completed as far as relevant. A report should be completed with some attachments: e.g.

paper/presentation given, publication or a report.

The dissemination reports will be included in the D2.2 deliverables on Month 12, 24 and 36.

Partner submitting report / suggestion

Partner name:

Personal name & first name:

Issue addressed

Journal Publication Advisory Board

3

Conference Paper4 Conference Presentation

Conference Session Conference Flyer / Documentation

Exhibition Booth Workshop Organized

Presentation at a National Event Press and Dissemination material5

Presentation to the third parties (e.g. Industry)

Title of Paper / Publication:

Authors:

Conference / Editor / Journal

Date(s)

Location

Title Conference / Journal

Volume/Number/Page (in case of Journal publications)

Initiating organisation (in case of a conference)

Contact of editor or organisation(web, mail, address)

2 Select report or suggestion

3 Details in the “Summary” section: ID of the expert, contact data, motivation

4 Attending meetings of other projects should be reported as a “collaboration activity”

5 Newspapers, newsletters, press releases, brochures, etc…

FP7-287800 SALUS


Other partners involved:

Supporting external parties:

Approximate number of persons attended (conference/workshops):

Abstract of Paper/Presentation - Summary of Event:

FP7-287800 SALUS


ANNEX 5 LIST OF EVENTS-CONGRESSES

Events - Congresses The Salus list of events / congresses intends to inform the partners on possibly interesting events and/or conferences, either to get domain related input or to

disseminate the SALUS options and developments.

The focus of our dissemination activities clearly lays on pharmacovigilance. An attempt is made to classify the events:

DEV Medical devices

eH eHealth (health IT in general) Reuse of data, EHR systems,

IT Information Technology

MED Medical Healthcare professional, Medical Practice

PH Pharmacy and Pharmacology

CT Clinical Trials

VIG Pharmacovigilance

I International

E European

N National

* Less relevant, not specifically focused on pharmacovigilance

** Relevant

*** The most relevant

The list will be update on regular basis, at least monthly.

FP7-287800 SALUS


Date of the list: 2013-01-01 Date Acronym Conference Title / Description Location Web site

Main

Focus

N/I Relevant

2012-04-18/20 Med@Tel Med@Tel by ISfTeH Luxembourg http://www.medetel.eu eH I **

2012-05-7/9 WoHIT2012 World of Health IT Copenhagen www.worldofhealthit.org eH I *

2012-05-24/25 UMC UMC Research Conference 2012 – Causality assessment

in an Evolving Pharmacovigilance Landscape. Uppsala, Sweden www.who-umc.org VIG I ***

2012-05-27/31 ESWC2012 9th

Extended Semantic Web Conference Heraklion,

Greece http://2012.eswc-conferences.org/ IT I **

2012-08-23/26 ICPE 2012 International Conference on Pharmaco-epidemilogy &

Therapeutic Risk Management Barcelona, Spain http://www.pharmacoepi.org VIG I ***

2012-08-26/29 MIE 2012 Medical Informatics Europe Pisa, Italy www.mie2012.it

www.efmi.org eH I *

2012-09-24/27 AAL Forum

2012 Ambient Assisted Living Forum 2012

Eindhoven, The

Netherlands www.aalforum.eu eH I **

2012-10-03/08 FIP 2012 Centennial FIP Congress – The Future of Pharmacy, be

part of the creation!

Amsterdam, The

Netherlands www.fip.org/amsterdam2012 PH I *

2012-10-08/12 DIA DIA Clinical Forum The Hague, The

Netherlands

www.diaeurope.org

VIG I **

2012-10-10/12 MedTech Eucomed MedTech Forum Brussels, Belgium www.medtechforum.eu DEV I *

2012-10-30/

11-02 ISOP2012

International Society of Pharmacovigilance Annual

Meeting Cancun, Mexico www.isoponline.org VIG I **

2012-11-14/17 Medica 2012 Medica Düsseldorf,

Germany www.medica.de IT I *

2012-11-18/20 HIMMS

CIO HIMMS Europe CIO Summit Mallorca, Spain www.hitleadershipsummit.eu IT I *

2012-11-19/20 Interoperability Workshop organised by the Center of

eHealth Sweden Lund, Sweden [email protected] eH E **

2013-01 DG Connect Concertation Meeting Secondaru Use of EHR data Brussels, Belgium

2013-02-18/22 EMA

Excellence

EMA – Excellence in Pharmacovigilance – Clinical

Trials and Post-Marketing – DIA Europe

London, United

Kingdom

www.diahome.org

VIG E ***

2013-03-3/7 HIMSS13 HIMSS13, the Annual Conference and Exhibition of Healthcare Information and Management Systems Society

New Orleans,

USA http://www.himssconference.org IT I *

2013-03-4/6 DIA Euro

2013 DIA Euromeeting

Amsterdam,

Netherlands

http://www.diahome.org/en/Flagship-

Meetings/13101-EuroMeeting.aspx VIG E ***

2013-04 P2T 2013 8ième Congrès P2T France www.congres-p2t.fr VIG N **

2013-04 conHIT Conference of German IT vendors association Berlin, Germany www.cohit.de/en IT N *

http://www.medetel.eu/

http://www.worldofhealthit.org/

http://www.who-umc.org/

http://2012.eswc-conferences.org/

http://www.pharmacoepi.org/

http://www.mie2012.it/

http://www.efmi.org/

http://www.aalforum.eu/

http://www.fip.org/amsterdam2012

http://www.diaeurope.org/

http://www.medtechforum.eu/

http://www.isoponline.org/

http://www.medica.de/

http://www.hitleadershipsummit.eu/

mailto:[email protected]

http://www.diahome.org/

http://imia.us1.list-manage1.com/track/click?u=0603f4221b87090e77cdb78bc&id=b844f7373a&e=a40e6f8483

http://www.diahome.org/en/Flagship-Meetings/13101-EuroMeeting.aspx

http://www.diahome.org/en/Flagship-Meetings/13101-EuroMeeting.aspx

http://www.congres-p2t.fr/

http://www.cohit.de/en

FP7-287800 SALUS


2013-04 Med@Tel Med@Tel by ISfTeH Luxembourg http://www.medetel.eu eH I **

2013-04-11/13 ISPE

MidYear ISPE Mid-Year Meeting Munich, Germany http://www.pharmacoepi.org VIG I ***

2013-04-17/19 EFMI STC

2013 EFMI STC (Special Topic Conference)

Prague, Czech

Republic http://www.stc2013.org/ IT E **

2013-04-18/19 BigData201

3 (HISA)

Australia's Big Data in biomedicine and healthcare

conference - biomedical informatics, personalised

medicine, health 2.0/participatory health, data

governance, data analytics and healthier outcomes.

Melbourne,

Australia http://www.hisa.org.au/page/bigdat

a2013 eH I *

2013-05-13/15 WoHIT2013 World of Health IT Dublin, Ireland www.worldofhealthit.org eH I **

2013-05 ECH European Connected Health Leadership Summit and

mHealth Forum www.echcampus.com I *

2013-05- UMC UMC Research Conference 2013 Uppsala, Sweden www.who-umc.org VIG I ***

2013-05-26/30 ESWC2013 10th

Extended Semantic Web Conference Montpellier,

France http://2013.eswc-conferences.org/ IT I **

2013-06-3/4 EUHealthData

2013

2013 European Summit on the Trustworthy Reuse of Health Data By invitation only:

http://bit.ly/2013_EU_SummitonTrustworthyReuseofHealthData

Brussels, BE http://euhealthdata2013.imia.info). eH E *

2013-08-17/18 Context Sensitive Health Informatics Pre-Medinfo2013

Copenhagen,

Denmark

www.cshi2013.org,

http://wp.me/pvCUS-1ql

eH I *

2013-08-20/23 Medinfo

2013 Medinfo

Copenhagen,

Denmark www.medinfo2013.dk eH I **

2013-08-25/28 ICPE 2013 International Conference on Pharmaco-epidemilogy &

Therapeutic Risk Management Montreal, Canada http://www.pharmacoepi.org VIG I ***

2013-08-31/ 09-

05 FIP 2013

World Congress of Pharmacy and Pharmaceutical

Sciences Dublin, Ireland www.fip.org PH I *

2013-09-1 AAL Forum

2013 Ambient Assisted Living Forum 2013

Norrköping,

Sweden www.aalforum.eu eH I **

2013-10-1/4 ISOP2013 International Society of Pharmacovigilance Annual

Meeting Pisa, Italy www.isoponline.org VIG I **

2013-11-20/23 Medica 2013 Medica Düsseldorf,

Germany www.medica.de IT I *

2013-11- HIMMS

CIO HIMMS Europe CIO Summit www.hitleadershipsummit.eu IT I *





http://www.stc2013.org/

http://imia.us1.list-manage.com/track/click?u=0603f4221b87090e77cdb78bc&id=8a20182b2d&e=a40e6f8483

http://imia.us1.list-manage.com/track/click?u=0603f4221b87090e77cdb78bc&id=8a20182b2d&e=a40e6f8483


http://www.echcampus.com/


http://2013.eswc-conferences.org/

http://imia.us1.list-manage1.com/track/click?u=0603f4221b87090e77cdb78bc&id=9b7234de83&e=a40e6f8483

http://imia.us1.list-manage1.com/track/click?u=0603f4221b87090e77cdb78bc&id=0e05ab5559&e=a40e6f8483

http://imia.us1.list-manage.com/track/click?u=0603f4221b87090e77cdb78bc&id=7114c02e61&e=a40e6f8483

http://imia.us1.list-manage1.com/track/click?u=0603f4221b87090e77cdb78bc&id=7ab91d9b3f&e=a40e6f8483

http://www.medinfo2013.dk/


http://www.fip.org/

http://www.aalforum.eu/


http://www.medica.de/

http://www.hitleadershipsummit.eu/



FP7-287800 SALUS


2014-05- WoHIT2014 World of Health IT Athens, Greece www.worldofhealthit.org eH I **

2014-05- UMC UMC Research Conference 2014 Uppsala, Sweden www.who-umc.org VIG I ***

2014-05- ESWC2014 11th

Extended Semantic Web Conference http://www.eswc-conferences.org/events IT I **

2014-08- ICPE 2014 International Conference on Pharmaco-epidemilogy &

Therapeutic Risk Management http://www.pharmacoepi.org VIG I ***

2014-08- MIE 2014 Medical Informatics Europe Istanbul, Turkey www.efmi.org eH I **

2014-10- ISOP2014 International Society of Pharmacovigilance Annual

Meeting www.isoponline.org VIG I **



2015-05- WoHIT2015 World of Health IT www.worldofhealthit.org eH I **

2015-08 Medinfo2015 Medinfo Sao Paolo, Brazil www.imia-medinfo.org eH I *



http://www.eswc-conferences.org/events


http://www.efmi.org/





http://www.imia-medinfo.org/

FP7-287800 SALUS


dx.x.x deliverable name - i-hd d2... · salus-fp7-287800• d2.2.1 • version 1.0 • january...

Documents